| Name | Title | Contact Details |
|---|
27North Inc. is a luxury expedition vehicle manufacturer, providing durable and luxurious vehicles tailored to suit adventure seekers, leisurely travelers, and mobile lifestyle enthusiasts. Since 2017, our team has provided our clients with the highest quality, first-class service. With our comprehensive offerings, you can expect to receive superior customer service from the initial contact and beyond.
® 2023 FSNB, N.A. Member FDIC. Equal Housing Lender. Equal Opportunity Employer.
Valent Partners are an integrated team of strategists, business leaders and technologists obsessed with helping our clients reach new heights. We approach each situation through a holistic business and technology lens, advising on and delivering solutions that help your organization adapt ahead of your competition. You have a goal. Well get you there. If your organization is interested in finding ways that technology can improve your performance, profitability, and growth, we can help. Contact Valent Partners today to arrange a consultation on the challenges you face. Your Digital Journey begins here.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Corporate Fleet Services specializes in the acquisition and sale of corporate jets. We have successfully completed hundreds of transactions Nationally and Internationally. It is rare that a Dealer can inventory the large corporate jets required in todays business environment. Few are in the position to structure the leasing, purchasing or delayed purchase options we offer. In addition to purchasing and selling aircraft, Corporate Fleet Services can act as your exclusive agent to either purchase or sell your current aircraft. Our research department is updating its files daily to stay ahead of market trends.